Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity
This study is about a rare condition known as CV2 autoimmunity, sometimes called CV2/CRMP5 paraneoplastic neurological syndrome. This condition happens when a cancer causes the body's immune system to mistakenly attack parts of its own nervous system, leading to various symptoms. The most common cancer linked to this is a type of lung cancer. We want to thoroughly investigate patients with CV2 antibodies to better understand their symptoms, how their immune system is involved, and what happens in their brain and nervous system. Currently, there isn't enough information about how this condition affects the brain and spinal fluid. By gathering more details, we hope to improve how doctors diagnose and treat patients, ultimately leading to better care.
At a glance
What is this study about?
You might be reading this because you, or someone you know, has a condition called CV2 autoimmunity. This is a very rare condition that happens when the body's immune system, which normally fights off infections, starts to attack its own tissues, particularly parts of the nervous system. This often happens because of a cancer elsewhere in the body, even if the cancer isn't directly in the nervous system. The cancer can trigger the immune system to make 'antibodies' that wrongly target healthy cells.
This study is trying to learn more about people who have these CV2 antibodies. We know that the symptoms can be very different from person to person, affecting the brain, spinal cord, and nerves. Currently, doctors don't fully understand all the ways this condition can affect the body, especially the brain and spinal fluid. The most common type of cancer linked to this condition is a small cell lung cancer.
The main goal of this study is to gather detailed information from a large group of patients with CV2 antibodies. By looking closely at their symptoms, how their immune system behaves, and the results of their medical tests (like scans or spinal fluid tests), we hope to build a much clearer picture of this complex condition. This will help doctors recognize and understand CV2 autoimmunity better, which is a crucial step towards developing better ways to diagnose and treat it, and ultimately improve patient care.
Key takeaways
- The study aims to understand CV2 autoimmunity, a rare condition linked to cancer.
- It focuses on how this condition affects the brain and nervous system.
- Data will come from reviewing existing medical records of patients.
- There are no direct risks or new procedures for participants.
- The goal is to improve diagnosis and treatment for future patients.
Who may be eligible?
This study is open to adults aged 18 and over, with no upper age limit, regardless of whether they are male or female.
To be considered for this study, you must have a neurological condition (a problem affecting your brain, spinal cord, or nerves) that is thought to be paraneoplastic. This means your neurological symptoms are caused by a cancer somewhere else in your body. Crucially, blood or spinal fluid tests must have shown that you have CV2 antibodies.
We would not be able to include you in the study if you do not have a neurological disorder or if tests have not shown the presence of CV2 antibodies in your blood or spinal fluid. Also, if there isn't enough medical information available about your condition, you wouldn't be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a neurological problem (affecting your brain, spinal cord, or nerves)?
- Have tests shown you have CV2 antibodies in your blood or spinal fluid?
- Is your neurological condition thought to be linked to a cancer?
- Your doctor has enough medical information about your condition to share.
What does participation involve?
This study involves reviewing your existing medical records and test results. You would not be asked to undergo any new tests, take new medication, or attend extra appointments. Your doctor would provide the research team with information collected from your routine care, such as your symptoms, results from blood tests, scans (like MRI), and possibly spinal fluid tests. There are no follow-up visits specifically for this study, as it uses information already gathered. The total duration of your participation would be how long it takes for your medical records to be reviewed by the research team.
Potential risks and benefits
Locations (1)
- Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier EstVerified postcodeBron, France
Common questions
What does 'paraneoplastic neurological syndrome' mean?
It means your nervous system symptoms are caused by a cancer elsewhere in your body, rather than the cancer being directly in your brain or nerves.
What are CV2 antibodies?
These are proteins made by your immune system that are mistakenly attacking healthy parts of your nervous system in people with this condition.
Will I have to take any new medicines or have extra tests?
No, this study only involves looking at your existing medical records; you won't need new medicines or extra tests specifically for the study.
Will taking part affect my medical care?
No, your medical care will not be affected in any way by whether you decide to take part or not.
How will my personal information be kept private?
Your data will be anonymised, meaning any information that could identify you will be removed to protect your privacy.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.